In plain terms

The claim being assessed: Replacing dietary saturated fat with linoleic-acid-rich oils reduces coronary heart disease events in adults.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: The preregistered primary-subclaim rule returns Γ from SC2. Sixty original reports provide strong experimental lipid effects and a substantial but conflicting clinical and prognostic context. The accessible exact trial evidence does not verify a positive oil-replacement coronary-event crossing; older positive trial reports remain inaccessible at primary-result depth. LA-rich oils were not silently redefined as chemically pure LA, and ALA-containing oils are not excluded simply because they contain ALA. Whole-diet or smoking cointerventions and shared metabolic instruments retain explicit limits. Weakest-link returns Α for carnivore superiority; primary-subclaim and scope-matched return Γ. The verdict does not endorse a blanket seed-oil-harm claim or suggest saturated fat or carnivore diets are clinically superior.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

LA-rich oil replacement reliably changes lipid markers; exact coronary-event benefit needs more careful source and intervention separation, while blanket inflammatory harm and carnivore superiority remain unproved.

Implications for health and treatment: The preregistered primary-subclaim rule returns Γ from SC2. Sixty original reports provide strong experimental lipid effects and a substantial but conflicting clinical and prognostic context. The accessible exact trial evidence does not verify a positive oil-replacement coronary-event crossing; older positive trial reports remain inaccessible at primary-result depth. LA-rich oils were not silently redefined as chemically pure LA, and ALA-containing oils are not excluded simply because they contain ALA. Whole-diet or smoking cointerventions and shared metabolic instruments retain explicit limits. Weakest-link returns Α for carnivore superiority; primary-subclaim and scope-matched return Γ. The verdict does not endorse a blanket seed-oil-harm claim or suggest saturated fat or carnivore diets are clinically superior.

Limits for individual care: 60 primary reports with 3 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 60 primary reports; claims: 65; verified: 65; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 57 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 5 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

LA-rich oil replacement reliably changes lipid markers; exact coronary-event benefit needs more careful source and intervention separation, while blanket inflammatory harm and carnivore superiority remain unproved.

Deciding experiment: Randomize adults with prospectively defined coronary risk to isocaloric replacement of a specified saturated-fat food source with a chemically characterized LA-rich oil, versus retained saturated-fat food and an independently specified unsaturated-oil comparator. Prespecify adjudicated fatal and nonfatal coronary events over multiple years, achieved dietary intake, trans-fat exposure, background omega3, medication stability and analysis. Use LDL/apoBand inflammatory measurements as candidate mediators, not as substituted clinical outcomes.

Belief versus evidence: The preregistered primary-subclaim rule returns Γ from SC2. Sixty original reports provide strong experimental lipid effects and a substantial but conflicting clinical and prognostic context. The accessible exact trial evidence does not verify a positive oil-replacement coronary-event crossing; older positive trial reports remain inaccessible at primary-result depth. LA-rich oils were not silently redefined as chemically pure LA, and ALA-containing oils are not excluded simply because they contain ALA. Whole-diet or smoking cointerventions and shared metabolic instruments retain explicit limits. Weakest-link returns Α for carnivore superiority; primary-subclaim and scope-matched return Γ. The verdict does not endorse a blanket seed-oil-harm claim or suggest saturated fat or carnivore diets are clinically superior.

Best-supported rival: Food-pattern and cointervention programmes improve coronary outcomes. Lyon's randomized clinical report (PMID7911176) separates a documented whole-pattern clinical benefit from an assumed LDL-mediated LA-rich oil benefit: events decreased while serum lipids stayed similar and LA intake fell. It does not prove LA harm, because other food and fatty-acid components changed simultaneously.

COMPETING MECHANISTIC MODELS

Rank 1: Food-pattern and cointervention programmes improve coronary outcomes (Ε). A dietary pattern together with relevant behaviour change can reduce coronary events without demonstrating an isolated LA-rich oil mechanism. Randomized Lyon (PMID7911176) and Oslo diet-antismoking (PMID6118715) programmes show clinical event reductions in their baseline-defined populations, with long-term follow-up PMID26924204. These programmes alter multiple foods or smoking, and their clinical success cannot identify the oil replacement component or a universal diet optimum.

Rank 2: Other lipid species and non-LDL pathways affect clinical response (Ε). Specific non-LA lipid exposures can modify coronary outcomes even when LDL changes do not differ, providing an alternative explanation for mixed-oil programme results. JELIS (PMID17398308) provides a positive allocated EPA clinical adjunct with the same statin-associated LDL fall, while Lyon's multi-fat diet (PMID7911176) reduced events without a serum-lipid difference. The inference is restricted to defined EPA adjunct and bundled diet contexts; it does not prove that ALA rather than LA explains every older trial or that LDL is causally irrelevant.

Rank 3: Composition, implementation and baseline context explain discordance (Γ). Oil constituents, food matrices, trans fat, adherence and baseline disease affect the net result of a nominal fat replacement. Minnesota and Sydney original Methods identify different historical exposures and implementation, DIVAS documents achieved replacement (PMID24717370), and coconut-butter-olive and rice-bran-sunflower trials (PMID29511019,16483027) show composition-sensitive markers. These explanatory factors were not factorially isolated against coronary outcomes across the old trials; retrospective explanations cannot erase their null or adverse results.

Rank 4: LA-rich oil replacement reduces coronary events (Γ). Replacing saturated fat with specified LA-rich oil causally lowers coronary-event incidence over at least one year. Controlled feeding lipid changes (PMID26016869), positive substitution associations (PMID26429077), and some genetic support (PMID33924952) favour the hypothesis. Accessible exact clinical trials are null or adverse, and old positive clinical scans were inaccessible; nonrandomized hospital periods and bundled diet programmes cannot silently supply exact-source verification.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Replacing dietary saturated fat with linoleic-acid-rich oils reduces coronary heart disease events in adults.

The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.

Selection: position 12 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T16:06:25.313824+00:00. Ranked editorial traffic priority rather than measured global popularity or a preset verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: The frozen framework has no dedicated clinical nutrition or cardiovascular-prevention rubric. Rubric 06's lifespan-specific wording is quoted unchanged, with an explicit clinical adaptation to controlled dietary replacement and adjudicated coronary events. Lipid markers, ectopic fat, inflammation, plaque surrogates, symptoms, coronary mortality and nonfatal coronary events remain distinct. The human clinical sources are not capped merely for involving one species; the literal single-species rule concerns animal-to-human inference. Genuine independently failing causal sets are not re-capped using their observational leg.

The registered question concerns coronary events after saturated fat is replaced with a specified LA-rich oil. It does not ask whether LDL can be lowered, whether chemically pure LA is the only active ingredient, or whether every modern seed oil is harmful. ALA-containing oils stay within the oil claim. Tissue, plasma and food-intake measurements are not interchangeable, and a favourable fatty-acid percentage can change through metabolism or changes in other lipids.

Feeding experiments provide strong evidence that these replacements can change lipid exposure. DIVAS's isoenergetic 16-week design lowered LDL cholesterol with omega6 replacement but its primary vascular response was null (PMID26016869). The article's estimated mortality reduction was extrapolated, not an observed event. Other food matrices show different lipid responses, including butter versus coconut or olive oil (PMID29511019) and rice-bran versus sunflower oil (PMID16483027). These findings establish physiology without resolving the event question.

The accessible Minnesota original report found no overall cardiovascular-event benefit despite cholesterol lowering (PMID2643423). Its later recovered-data component shares that parent trial. Actual recovered Methods state that complete randomized raw data were unavailable and only 149 of 295 autopsy files were recovered. Longitudinal cholesterol decline predicted death across both arms, which is not randomized proof that lipid lowering harms patients. The 2024 correction updates a thesis link rather than outcome numbers (PMID38942429, attached to the parent).

Sydney's recovered original clinical data showed increased cardiovascular and coronary mortality after high LA safflower-oil and margarine substitution; the actual all-cause P=.051 was borderline (PMID23386268). The high intake and historical products limit extrapolation to ordinary modern oils, and the trial did not isolate an inflammatory mediator. Its accompanying meta-analysis is not counted as original primary evidence. Finnish hospital-period male results were favourable and female results nonsignificant, but these were period-level controlled observations rather than patient randomization (PMID393644,6840954).

Positive dietary-pattern coronary programmes remain important. Lyon reduced events with a Mediterranean alpha-linolenic-rich pattern while linoleic intake fell and serum lipids remained similar (PMID7911176); Oslo's 1981 programme combined diet and smoking changes (PMID6118715). These cannot be attributed to one oil component. Older VA and Oslo Diet-Heart primary clinical scans were identified but inaccessible from the tested public services, so their reported positive clinical outcomes are not fabricated or treated as nonexistent; they remain a verification gap before assigning a positive exact-scope clinical crossing.

Prospective and genetic sources offer substantial context, not a uniform answer. NHS/HPFS modelled replacement (PMID26429077), EPIC Norfolk circulating fatty acids (PMID22802735) and CHS mortality (PMID25124495) are favourable, whereas Dutch dietary exposure, Danish adipose LA and MESA or Framingham analyses are null (PMID21816117,33687534,24351702,30572606). Positive LA genetic estimates (PMID33924952) coexist with inconsistent results and FADS/lipoprotein sensitivity (PMID35692035). Genetic evidence is considered as causal inference on its assumptions, without equating a lifelong circulating-metabolism perturbation to isocaloric oil substitution.

Human feeding does not support a blanket clinically important inflammatory-harm claim at ordinary exposure. Bjermo's isocaloric trial found lower liver fat and selected inflammatory markers with omega6 replacement, while some lipid benefits were reported in postrandomization compliant subsets (PMID22492369). FADSDIET suggested genotype-dependent CRP responses without a randomized saturated-fat comparator (PMID30624587). These results require neither universal harm nor universal safety declarations. Carnivore surveys report real perceived benefits but contain no controlled long-term event comparison; high LDL findings and low triglycerides do not cancel each other by assumption (PMID34934897,40385902).

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim rule returns Γ from SC2. Sixty original reports provide strong experimental lipid effects and a substantial but conflicting clinical and prognostic context. The accessible exact trial evidence does not verify a positive oil-replacement coronary-event crossing; older positive trial reports remain inaccessible at primary-result depth. LA-rich oils were not silently redefined as chemically pure LA, and ALA-containing oils are not excluded simply because they contain ALA. Whole-diet or smoking cointerventions and shared metabolic instruments retain explicit limits. Weakest-link returns Α for carnivore superiority; primary-subclaim and scope-matched return Γ. The verdict does not endorse a blanket seed-oil-harm claim or suggest saturated fat or carnivore diets are clinically superior. Sensitivities: weakest-link Α; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[18] The original Minnesota randomized institutional trial lowered serum cholesterol but found no overall cardiovascular-event, cardiovascular-death or total-mortality difference. Mean dietary exposure was 384 days despite a 4.5-year trial and many short stays; intervention changed dietary cholesterol and historical fat sources, and later recovered reports share this trial.

[21] The Finnish two-hospital crossover found about half the male electrocardiographic-coronary or coronary-death incidence during lower-saturated higher-polyunsaturated dietary periods. Although metadata labels randomized trial, the described allocation is hospital-period diet reversal and should not be treated as patient randomization; mixed dietary changes and historical context restrict isolated linoleic inference.

[22] The Finnish women's hospital-period intervention lowered cholesterol and coronary incidence estimates, but the coronary difference was not statistically significant. Shared hospital-period design and possible medication or population changes limit inference; nonsignificance is not proof of equivalence, and male/female reports are grouped under one parent study.

[31] The 195-person 16-week isoenergetic DIVAS trial lowered LDL cholesterol with saturated-fat replacement by omega6 PUFA, but its primary flow-mediated-dilatation endpoint was null. Its estimated 17-20% mortality reduction was extrapolated from lipid change and was not an observed mortality or coronary-event result; mixed monounsaturated replacement and short follow-up retain scope.

[39] A 67-person 10-week isocaloric randomized vegetable omega6 versus butter trial found lower liver fat and selected inflammatory signalling markers with PUFA, without a proinflammatory or oxidative-stress signal. Some favourable lipid estimates were restricted to postrandomization compliant participants and cannot define clinical beneficiaries; markers and liver fat are not coronary outcomes or universal safety proof.

[40] A 2029-person social-media carnivore survey reported perceived symptom and weight improvements alongside high satisfaction and high LDL cholesterol in a laboratory-reporting subset. Maintainer recruitment, self-report, missing measurements and no concurrent comparison prevent long-term cardiovascular superiority or clinical event safety conclusions.

[42] Original recovered Minnesota trial analyses confirmed cholesterol lowering without a reported mortality benefit; selected autopsy files and longitudinal cholesterol-mortality associations challenged a simple marker-to-benefit prediction. Only the original recovered-data component earns primary credit: full randomized raw data were unavailable and autopsies partly recovered; cholesterol-death association in both arms is not randomized mediator harm, and the examined 2024 erratum PMID38942429 updates a thesis link rather than study numbers.

[43] Original recovered Sydney data from 458 post-coronary-event men showed lower cholesterol but higher coronary and cardiovascular mortality under safflower-oil and margarine substitution over median 39 months. Only recovered original trial data earns credit, not its meta-analysis; actual all-cause P=.051 was borderline, historical margarine and high LA exposure constrain usual-modern-oil inference, and an unspecified erratum attaches.

Tally: 0 positive qualifying study units across scoped subclaims; 8 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. No positive exact allocated oil-replacement coronary-event unit is counted at the recorded primary-access depth; this is a verification boundary, not evidence that inaccessible historical results do not exist. Positive whole-pattern, smoking and EPA clinical contrasts retain their intervention scope and do not inflate SC2's oil-specific tally. Original recovered-data reports count as reports of their parent studies; meta-analysis components, corrections, protocols and inaccessible abstract-free scans do not add original examination credit. Primary source count includes controlled feeding, mechanistic context, prospective cohorts and companion carnivore reports; it is not a count of sixty clinical oil trials.

No positive field-valid crossing was verified for the registered causal scope in this bounded audit. Pivotal null or negative tests remain informative; their implications depend on comparator quality, target engagement, power and the registered scope.

Cap audit, precedence and Β/Γ/Δ boundary

Clinical or natural-experiment evidence is assessed within its actual dietary package, allocation and endpoint scope. The marker cap binds feeding-derived predictions rather than automatically downgrading a genuinely convergent exact-scope set. Here the missing bridge is a verified positive clinical oil-swap crossing, not a rule that all nutrition or all human-only work must remain low. Mixed ALA-containing LA-rich oils stay eligible; pure-LA molecular specificity is a separate question.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Lipid, inflammatory, oxidative and vascular-surrogate changes do not substitute for coronary events. A null or opposite clinical comparison is a discriminator, not a positive threshold crossing. Positive feeding effects retain their biomarker scope, while available prospective and genetic support is considered directly rather than ignored. Inaccessible older clinical sources are logged as access gaps, not retractions or nonexistent trials. Oil replacement is not silently narrowed to isolated pure LA; ALA content is recorded as a component and mechanistic limit.

SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Controlled replacement trials, including DIVAS and Minnesota, establish lipid lowering in their experimental contexts. The proposed LDL-related exposure is an intermediate marker for coronary events, so its downstream clinical inference retains Γ. This does not imply that the directly measured lipid change is doubtful or that LDL causality elsewhere is refuted.

SC3 cap: “Biomarker change without functional/phenotypic change caps at Γ.” The usual-exposure inflammatory-harm claim lacks a verified clinical inflammatory coronary endpoint. Controlled omega6 feeding has neutral or favourable inflammatory markers in several experiments; FADSDIET shows genotype-dependent short marker responses without randomized saturated-fat comparison. Sydney's historical high-dose intervention harm does not isolate inflammation or establish toxicity of all modern seed oils. Biomarker-only inference cannot exceed Γ.

SC4 cap: “Use when the hypothesis is mostly a grand narrative with weak intervention support.” No examined controlled long-term cardiovascular comparison establishes carnivore superiority. Two original carnivore empirical reports contain self-selected perceived benefits and lipid changes, without adjudicated event comparisons; extrapolating these to established long-term superiority remains Α. Positive subjective experiences are retained, not dismissed as fabricated.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Controlled replacement trials, including DIVAS and Minnesota, establish lipid lowering in their experimental contexts. The proposed LDL-related exposure is an intermediate marker for coronary events, so its downstream clinical inference retains Γ. This does not imply that the directly measured lipid change is doubtful or that LDL causality elsewhere is refuted.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. In the actually examined exact clinical sources, Minnesota reports no cardiovascular-event benefit and Sydney reports increased coronary mortality. Positive Finnish hospital-period observations and bundled Oslo or Lyon programmes retain their allocation and composition limits. The older VA and Oslo Diet-Heart primary clinical scans could not be accessed, so their reported positive results are explicitly unverified here. No verified positive allocated oil-replacement coronary-event crossing was identified at this evidence-access depth; the Step 9 unclear-positive boundary holds the precise registered claim at Γ rather than promoting lipid changes or second-hand trial summaries. This is a bounded verification verdict, not proof that LA-rich oils have no benefit.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. The usual-exposure inflammatory-harm claim lacks a verified clinical inflammatory coronary endpoint. Controlled omega6 feeding has neutral or favourable inflammatory markers in several experiments; FADSDIET shows genotype-dependent short marker responses without randomized saturated-fat comparison. Sydney's historical high-dose intervention harm does not isolate inflammation or establish toxicity of all modern seed oils. Biomarker-only inference cannot exceed Γ.

SC4 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. No examined controlled long-term cardiovascular comparison establishes carnivore superiority. Two original carnivore empirical reports contain self-selected perceived benefits and lipid changes, without adjudicated event comparisons; extrapolating these to established long-term superiority remains Α. Positive subjective experiences are retained, not dismissed as fabricated.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Controlled isoenergetic feeding can identify a lipid-exposure response, but the registered clinical event is assessed separately; marker change is not itself a clinical threshold crossing.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): The field-valid clinical equivalent is allocated saturated-fat replacement by specified LA-rich oil against a retained comparator with a positive adjudicated coronary-event difference over at least one year. Oil mixtures are legitimate specified exposures; unrelated diet, smoking or medication changes cannot be silently assigned to oil substitution. Accessible primary results and actual endpoint hierarchy are required.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): The phenotype is clinically important inflammatory cardiovascular harm at ordinary food exposures, requiring a direct clinical outcome and evidence that inflammation mediates it. Acute signalling, CRP, oxidative markers and extreme historical oil diets remain separate inference classes.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): The clinical primacy claim requires defined carnivore and balanced patterns compared on long-term adjudicated cardiovascular outcomes. Survey satisfaction, uncontrolled weight loss and selected laboratory values cannot establish superiority.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for the inference from lipid-response experiments to clinical coronary protection; direct lipid lowering remains an observed experimental effect.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered as an animal-generalization rule for directly studied human clinical outcomes. The clinical dietary adaptation is explicit; the boundary fails because a positive exact clinical crossing was not verified, not because only humans were studied.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Triggered for the claimed inference from CRP, eicosanoids or oxidative signals to inflammatory coronary harm at usual exposures.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Link the allocated lipid response to a functional clinical endpoint or independently identify its mediation; marker reproducibility alone does not cross the registered clinical threshold.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Obtain and verify original positive historical oil-trial results with their exact endpoint and composition, then test modern specified oil replacement with adjudicated coronary outcomes over a prespecified horizon. The clinical inference must survive implementation, competing exposures and allocation limitations.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Directly demonstrate clinically important inflammatory coronary harm under usual LA-rich food replacement, with mediator dissociation and a retained comparator rather than short marker correlations or historical product extrapolation.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A controlled, baseline-defined, long-term comparison of an exact carnivore pattern against a specified balanced pattern must show superior adjudicated cardiovascular outcomes, with comparable energy, support and medication management.

Upper ladder: Genetic LA and omega6 analyses and Finnish hospital-period natural experiments were evaluated as real evidence with distinct confounders. They do not automatically form a positive exact-scope set: circulating metabolic instruments differ from assigned dietary replacement, results and pleiotropy sensitivity conflict, and historical hospital periods can confound diet with other changes. No universal association cap is reapplied to an independently convergent same-scope case; the positive exact clinical bridge was not verified at this access depth.

Independence: No model or subclaim is assigned Ζ or above. Reports sharing Minnesota, DIVAS, LIPOGAIN, STRIP or Oslo participants are one study; repeated cohort biomarker measurements and reused UK Biobank/FADS instruments do not become independent lines by resolution or laboratory. Genetic and dietary allocation would fail differently if they tested the same exposure and endpoint validly, but that exact-scope conjunction is not established here.

Falsification and pitfalls

Confirmation by biomarker. Observed LDL lowering and a predicted mortality reduction in DIVAS are not measured coronary-event prevention.

Mechanism conflation. LA-rich oil substitution is not identical to pure LA, total PUFA, an omega6-to-omega3 ratio, repeated frying, Mediterranean patterns or carnivore diets.

Therapeutic effect misread as mechanistic proof. Whole-pattern or EPA adjunct benefit does not identify a single LA or LDL mediator.

Scope fitted to the result. Postrandom compliance, long-stay survivor cohorts and diet maintainers do not define baseline clinical beneficiaries.

Negative field-valid perturbation read as a crossed threshold. Minnesota nulls, Sydney adverse results and conflicting MR do not become positive evidence merely because their design is informative.

Replication confused with reproduction. Minnesota, Finnish hospital periods, DIVAS, LIPOGAIN, STRIP and Oslo follow-ups are grouped by study; molecular-resolution and follow-up reports are not independent causal lines.

Association dressed as mechanism. Cholesterol-death covariance pooled across both Minnesota arms and circulating-fatty-acid percentages do not constitute randomized mediator harm or food-replacement exposure.

Adversarial steelman: above, then below

The strongest Δ case combines predictable lipid lowering, positive cohort substitution estimates, favourable fatty-acid genetic studies and historically reported positive VA or Oslo Diet-Heart outcomes. Because the claim concerns LA-rich oils rather than pure LA, an ALA-containing oil is not disqualified. A verified positive clinical oil replacement result could cross the first clinical threshold even if its mechanism is mixed.

The strongest Β case notes that accessible randomized exact clinical oil-replacement data are null or harmful and many positive sources are marker or association studies. If the proposal were only a correlation-based clinical narrative, Β would describe it. However, controlled feeding provides partial experimental system support and the broader mixed clinical evidence cannot be discarded as no intervention science at all.

The higher case is blocked by missing original-result verification for the older positive clinical anchors and by uncontrolled component attribution in the available bundled positives, as required by Step 9's positive exact-scope test. The lower case is rejected because the proposed mechanism has genuine controlled physiological support and clinically informative perturbations, even though the positive coronary crossing is not verified here. This access-constrained grade is revisable and does not declare the broad oil-benefit literature refuted.

Final score, causal direction and M/S/D

The preregistered primary-subclaim rule returns Γ from SC2. Sixty original reports provide strong experimental lipid effects and a substantial but conflicting clinical and prognostic context. The accessible exact trial evidence does not verify a positive oil-replacement coronary-event crossing; older positive trial reports remain inaccessible at primary-result depth. LA-rich oils were not silently redefined as chemically pure LA, and ALA-containing oils are not excluded simply because they contain ALA. Whole-diet or smoking cointerventions and shared metabolic instruments retain explicit limits. Weakest-link returns Α for carnivore superiority; primary-subclaim and scope-matched return Γ. The verdict does not endorse a blanket seed-oil-harm claim or suggest saturated fat or carnivore diets are clinically superior.

For the precise beneficial-coronary-trajectory account, the examined exact-scope evidence does not demonstrate the proposed positive causal dependency in either direction; Step 2 therefore returns epiphenomenon for that account. This label is not an assertion that oils are biologically inert: allocated feeding effects, adverse historical clinical contrasts and broader dietary benefits remain explicitly reported. It names the unisolated proposed benefit mechanism, not all physiology of the exposure.

Momentum: Mechanistic only. Modern DIVAS lipidomic analyses (PMID37062359), FADS-response work (PMID30624587,38714425) and circulating-PUFAMR(PMID40199060,35692035) investigate mechanisms or genetic proxies; no verified pending modern exact oil-swap coronary-event trial was identified.

Stability: Stable. No named verified pending exact clinical result was identified. The concrete upward trigger is primary verification of a positive old oil trial or a new allocated event trial; an access gap alone does not establish that the result will be positive.

Divergence: Contested. No manufactured field consensus or arithmetic gap. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Randomize adults with prospectively defined coronary risk to isocaloric replacement of a specified saturated-fat food source with a chemically characterized LA-rich oil, versus retained saturated-fat food and an independently specified unsaturated-oil comparator. Prespecify adjudicated fatal and nonfatal coronary events over multiple years, achieved dietary intake, trans-fat exposure, background omega3, medication stability and analysis. Use LDL/apoBand inflammatory measurements as candidate mediators, not as substituted clinical outcomes.

Readout: Adjudicated coronary events with prespecified endpoint hierarchy, intention-to-treat effect estimates and intervals; achieved energy and fatty-acid composition; apoB/LDL, inflammatory signals and safety outcomes. Controls: Comparable energy, dietary support, cointerventions and modern prevention care; characterized oils; explicit ALA and trans-fat content; stable medication; complete participant follow-up. Supporting: A positive allocated oil-replacement coronary-event contrast that replicates and maps baseline-defined boundaries; independently informative mediation supports a higher mechanistic claim. Falsifying: No clinical benefit despite adequate verified substitution and follow-up, or benefit confined to other cointerventions; adverse events must remain in the analysis and cannot be removed by defining responders.

KNOWLEDGE GAPS

Accessible primary-result verification of the old VA, Oslo Diet-Heart, MRC soybean and Rose clinical studies, with actual composition and endpoint hierarchy

Modern long-term allocated oil-swap coronary-event trials with contemporary prevention care

Distinct causal identification of dietary LA-rich oil exposure versus circulating fatty-acid metabolism and shared FADS or lipoprotein instrument pathways

Usual-intake inflammatory coronary harm versus high-dose historical margarine, repeated heating and short biomarker changes

Food-matrix and comparator effects, including saturated-fat sources, refined carbohydrate replacement and mixed omega3/omega6 oils

Defined carnivore patterns assessed against an active balanced comparator on actual cardiovascular events rather than maintainer surveys

REVIEWER NOTES

Sixty original reports were actually presented and individually appraised, most at abstract/status depth. Selected original Methods/Results were examined for Minnesota recovered data, Sydney recovered data and the 2021 carnivore survey. The 2024 Minnesota notice text was checked separately. Old VA, Oslo Diet-Heart, MRC soybean and Rose primary records were found, but no clinical-scan results were invented when public access failed. Consensus Pro and two SciSpace discovery queries support source discovery and aspect reconciliation; provider counts are not examined-primary counts. No full-paper audit, blind calibration or independent scientific peer review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Actual original Methods/Results show that the detailed longitudinal cohort comprised 2355 people exposed for at least one year, full randomized raw data were not recovered, and the adjusted cholesterol-death association pooled both arms with no detected cholesterol-by-arm interaction. This is observational mediator covariance, not randomized proof that cholesterol lowering causes death. The broader 9423 cohort's mortality graphs and the 149 partially recovered autopsies are separate evidence components. Original PMID27071971.

Actual selected original Results give all-cause P=.051, a borderline result rounded in the abstract; coronary and cardiovascular mortality contrasts were significant. The 458 men, median 39-month horizon and high LA safflower-oil/margarine intervention are verified, while usual-modern-oil toxicity and an inflammatory mediator are not demonstrated. Original PMID23386268.

The original 1989 trial abstract agrees for overall cardiovascular events and mortality. It also reports a mean dietary exposure of 384 days despite the longer trial, and the institutional food replacement changed several lipid-related features. The 1989 and 2016 reports belong to one parent trial; the recovered report's meta-analysis does not count as an additional original clinical experiment. Original PMID2643423.

The actual Finnish abstract describes one hospital on the diet, the other as control, then reversal after six years. Despite an RCT metadata tag, this is treated as a controlled hospital-period natural experiment, with the male favourable result retained and the women's nonsignificant report grouped under the same parent programme. Original PMID393644.

The original DIVAS trial confirms 16-week isoenergetic replacement and lower LDL but a null primary flow-mediated-dilatation endpoint. Its 17-20% mortality reduction was estimated from lipid change, not observed. This source supports experimental lipid response, not a coronary-event crossing. Original PMID26016869.

The original 67-person randomized isocaloric trial found lower liver fat and selected inflammatory signals with vegetable omega6 versus butter and no reported oxidative-stress or proinflammatory signal. Some lipid findings were restricted to postrandomization compliant participants. Short markers cannot prove universal safety or long-term event protection, but the unfavourable-inflammation prediction did not hold in this experiment. Original PMID22492369.

Actual original Methods confirm recruitment through existing carnivore social-media communities and at least six months of diet maintenance, with self-reported measurements and no balanced-diet control. Selected Results retain perceived benefits, improved glycemic reports and high LDL without converting these into adjudicated long-term cardiovascular superiority. Original PMID34934897.

The originalLyonallocated programme lowered coronary events while LA intake decreased and ALA/oleic exposure increased, with similar serum lipids. It is a positive whole-pattern result and does not prove LA harm. More generally, our registered claim is LA-rich oils, not pure LA, so an ALA-containing oil is not excluded merely for containing ALA. Original PMID7911176.

The examined original MR reports favourable linoleic-CAD estimates using allele scores and pleiotropy-robust summary methods. It is retained as causal-inference support, while the exposure is lifelong circulating metabolism rather than assigned isocaloric oil replacement. It does not independently verify the clinical dietary bridge. Original PMID33924952.

The original large PUFAGWAS/MR report found inconsistent linoleic estimates across methods and endpoints and important LDL/FADS locus sensitivity. Those assumptions and shared metabolic pathways are examined rather than treating every MR paper as either simple association or independently convergent proof. Original PMID35692035.

FADSDIET provides a relevant qualification: short CRP and fatty-acid responses differed by FADS1 genotype among 62 men receiving enrichment. There was no randomized saturated-fat comparator and no clinical coronary inflammatory endpoint. The result narrows a universal no-marker-response claim without establishing usual-intake clinical harm. Original PMID30624587.

The originalDanish case-cohort study found no adipose LA association with infarction after 16 years or shorter horizons. That null is retained alongside favourable CHS and EPIC Norfolk associations, preventing selective citation of only positive or adverse cohorts. Original PMID33687534.

The originalDutch 20,069-person study found no coronary incidence association across LA intake differences mainly replacing carbohydrate. It is not a randomized saturated-fat replacement trial, so its null cannot directly refute the registered oil-swap proposition. Original PMID21816117.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Replacing Saturated Fat with Linoleic-Acid-Rich Oils

Selected publication milestones, not an exhaustive history or discovery priority claim.

1966 — 1966 prolonged randomized Veterans feeding documents lipid lowering and tissue-linoleic enrichment; this examined report does not supply coronary-event outcomes. Original PMID5900208.

1979 — 1979 Finnish hospital-period male coronary findings are favourable under controlled dietary reversal, with allocation and period confounding retained. Original PMID393644.

1983 — 1983 the Finnish women's companion reports a nonsignificant coronary difference despite lipid lowering, illustrating endpoint and context limits. Original PMID6840954.

1989 — 1989 the Minnesota original clinical report finds no overall cardiovascular-event or mortality benefit despite cholesterol lowering. Original PMID2643423.

1994 — 1994 Lyon demonstrates clinical benefit from a mixed Mediterranean dietary pattern, without isolating an LA-rich oil component. Original PMID7911176.

2012 — 2012 an isocaloric vegetable omega6-versus-butter experiment finds no proinflammatory signal and lower liver fat, with biomarkers kept separate from coronary events. Original PMID22492369.

2013 — 2013 Sydney recovered participant data reveal an adverse coronary-mortality contrast under a high LA historical intervention; the meta-analysis is counted separately from original-data credit. Original PMID23386268.

2015 — 2015 DIVAS improves lipid markers but not its primary vascular outcome; estimated mortality benefit remains an extrapolation. Original PMID26016869.

2015 — 2015 long-term dietary substitution models favour PUFA and whole-grain replacement over refined carbohydrates, while allocation remains observational. Original PMID26429077.

2016 — 2016 the recovered Minnesota analysis adds original longitudinal and partial-autopsy information to the same parent trial; the clinical null is not a new independent trial. Original PMID27071971.

2019 — 2019 FADSDIET reports genotype-dependent short marker responses, requiring prospective controlled clinical validation. Original PMID30624587.

2021 — 2021 a large carnivore-maintainer survey records perceived benefits and lipid uncertainty without a long-term cardiovascular comparison. Original PMID34934897.

2021 — 2021 fatty-acid genetic analysis supports selected linoleic-CAD estimates, with endogenous-metabolism scope retained. Original PMID33924952.

2022 — 2022 a larger PUFAGWAS/MR analysis finds inconsistent cardiovascular estimates and lipoprotein/FADS locus sensitivity. Original PMID35692035.

2025 — 2025 a small German carnivore pre/post study reports perceived benefits and increased LDL rather than adjudicated clinical superiority. Original PMID40385902.

2025 — 2025 observational and genetic analyses report sex-specificomega6-CAD support, without equating plasma percentages to an allocated oil substitution. Original PMID40199060.

Research gaps

Accessible primary-result verification of the old VA, Oslo Diet-Heart, MRC soybean and Rose clinical studies, with actual composition and endpoint hierarchy

Modern long-term allocated oil-swap coronary-event trials with contemporary prevention care

Distinct causal identification of dietary LA-rich oil exposure versus circulating fatty-acid metabolism and shared FADS or lipoprotein instrument pathways

Usual-intake inflammatory coronary harm versus high-dose historical margarine, repeated heating and short biomarker changes

Food-matrix and comparator effects, including saturated-fat sources, refined carbohydrate replacement and mixed omega3/omega6 oils

Defined carnivore patterns assessed against an active balanced comparator on actual cardiovascular events rather than maintainer surveys

Boundary experiment

Randomize adults with prospectively defined coronary risk to isocaloric replacement of a specified saturated-fat food source with a chemically characterized LA-rich oil, versus retained saturated-fat food and an independently specified unsaturated-oil comparator. Prespecify adjudicated fatal and nonfatal coronary events over multiple years, achieved dietary intake, trans-fat exposure, background omega3, medication stability and analysis. Use LDL/apoBand inflammatory measurements as candidate mediators, not as substituted clinical outcomes.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1 (HSEF v5.3 pipeline). Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. All 60 REFERENCES PMIDs were re-verified against PubMed metadata: 60/60 resolve to the stated title, first author, journal and year, and 60/60 printed DOI strings match the PubMed DOI field exactly, including the four records for which PubMed holds no DOI. No reference carries a retraction or expression of concern; the attached erratum and update identifiers (PMID 38942429 on the Minnesota recovered-data report, PMID 28673906, PMID 32371385, PMID 34694867, and the UpdateOf preprint PMID 36711941) each resolve to a Published Erratum or preprint of the stated parent article. Fifteen load-bearing numeric and directional claims were checked against the original abstracts: DIVAS (195 participants, 16-week isoenergetic design, LDL-cholesterol fall, null flow-mediated-dilatation primary endpoint); Minnesota 1989 (384-day mean dietary exposure in a 4.5-year trial, no cardiovascular-event, cardiovascular-death or total-mortality difference); Minnesota recovered data (9423 randomised cohort, 2355 participants exposed for a year or more, 149 completed autopsy files); Sydney recovered data (458 men, higher coronary and cardiovascular mortality, borderline all-cause result); Lyon (605 post-infarct patients, about 27 months, lower linoleic intake, similar serum lipids); the Finnish Mental Hospital Study (hospital-level allocation with reversal after six years, about half the coronary incidence during the cholesterol-lowering periods, and a nonsignificant women's companion); JELIS (18 645 patients, 4.6 years, composite endpoint reduced, coronary death not different); Bjermo (67 randomised, 10 weeks, lower liver fat, no proinflammatory signal, compliant-subset lipid findings); Li 2015 (5% energy replacement, 25% lower coronary risk); Khaw 2018 (four weeks, higher LDL cholesterol on butter); FADSDIET (62 men, 4-week linoleic enrichment, genotype-dependent hsCRP); de Goede 2012 (20 069 participants, null coronary association, carbohydrate as the displaced nutrient); Lennerz 2021 (2029 respondents, markedly elevated LDL cholesterol, optimal triglycerides); and Park 2021 (allele-score and pleiotropy-robust linoleic estimates). All fifteen were supported as stated. Scoring logic was re-derived against the frozen HSEF v5.3 SKILL.md and hsef-framework.md.

Rejected findings (checked, no change).

1. Headline letter and aggregation. preregistration.json declares rule "primary-subclaim" with primary "SC2" and a UTC timestamp matching the review text, and the derivation reports the primary-subclaim result (Gamma from SC2) with weakest-link (Alpha) and scope-matched (Gamma) as declared sensitivities. SC2's own scope - randomized allocation, adjudicated coronary events over at least one year - matches the central claim, so scope-matched and primary-subclaim coincide here, and the Alpha on SC4 is a narrower subclaim reported separately, as the rule requires. No change.
2. Beta/Gamma boundary. Beta would require a claim resting on correlation with no intervention science. Controlled isoenergetic feeding trials (DIVAS, Bjermo, LIPOGAIN, STRIP) supply partial experimental system support, while Delta would require an intervention moving the registered clinical endpoint, which is not verified. Gamma stands.
3. Causal role. "epiphenomenon" is derived at framework Step 2 (no demonstrated causal dependency in either direction) and is explicitly scoped to the proposed beneficial-coronary-trajectory account rather than to the exposure's physiology. Correct as written.
4. Momentum. "Mechanistic only" is right: the named artifacts (DIVAS lipidomics PMID 37062359, FADS-response work, circulating-PUFA Mendelian randomization) are mechanistic or genetic, and no pending allocated oil-swap coronary-event trial is named. Momentum modifies no letter.
5. Collective-author defect. No reference in this package has a consortium first author, so the dropped-collective-author rendering bug does not occur here.
6. The Finnish Mental Hospital Study treated as a natural experiment. PubMed tags PMID 393644 as a randomized controlled trial, but the abstract itself describes hospital-level diet allocation with reversal after six years. Declining to count it as patient randomization is a defensible reading of the source, and the review states the tension explicitly.
7. The PubMed title field for reference 36 drops the italicised gene name "Apolipoprotein E". Per the standing convention, not an error.
8. Print/issue year versus e-pub year. No reference differs by more than the accepted plus or minus one year.
9. "Best-supported rival" line. Checked against the scorecard: models_evaluated[0] is rank 1 with is_nominal false and the review prints that rank-1 rival, so the renderer defect that prints the nominal model as its own rival does not occur here. The nominal is rank 4.
10. Spliced-provenance artifacts. This package carries no 9 October 2026 consensus-consistency block and no "earlier adversarial approval" clause, so neither the false-approval boilerplate nor the reviewer-notes contradiction reported elsewhere in this round can occur here. Verified by search.

Residual limitations. The erratum identifiers for references 2, 5 and 43 could not be resolved from the retrieved metadata fields and remain recorded as not supplied. Three sources were examined at partial-body depth and 57 at bounded abstract/status depth, so figures quoted from full text (149 of 295 autopsy files, the median 39-month Sydney horizon, the all-cause P = .051) were checked against the package's own retrieval receipts rather than independently re-extracted. The scorecard and provenance header name the generating system "Codex"; this adversarial review does not alter package-level provenance strings. No independent blinded calibration is claimed.

Validator. The frozen HSEF v5.3 validator was re-run on the revised scorecard and prose: 32 pass, 0 warn, 1 fail. The single failure is v5.lay_summary, which the validator itself marks "mandatory from v5.4" and which therefore does not apply to this v5.3 package. All v5.3 checks pass, including logic.aggregation, logic.cap_ceiling, logic.boundary_gamma, v5.ledger (60 sources / 65 claims) and v5.provenance.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Renaud S, de Lorgeril M, Delaye J et al. Cretan Mediterranean diet for prevention of coronary heart disease. The American journal of clinical nutrition. 1995. PMID 7754988. DOI: 10.1093/ajcn/61.6.1360S. Access: abstract_metadata. Study: Lyon_Diet_Heart_605.

2. de Lorgeril M, Renaud S, Mamelle N et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet (London, England). 1994. PMID 7911176. DOI: 10.1016/s0140-6736(94)92580-1. Access: abstract_metadata. Study: Lyon_Diet_Heart_605.

3. Satizabal CL, Samieri C, Davis-Plourde KL et al. APOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and Mortality. Stroke. 2018. PMID 30571417. DOI: 10.1161/STROKEAHA.118.022132. Access: abstract_metadata. Study: Framingham_and_3C_fatty_acid_cohorts.

4. Ornish D, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet (London, England). 1990. PMID 1973470. DOI: 10.1016/0140-6736(90)91656-u. Access: abstract_metadata. Study: PMID1973470.

5. Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (London, England). 2007. PMID 17398308. DOI: 10.1016/S0140-6736(07)60527-3. Access: abstract_metadata. Study: PMID17398308.

6. Jimenez-Torres J, Alcalá-Diaz JF, Torres-Peña JD et al. Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial. Stroke. 2021. PMID 34372670. DOI: 10.1161/STROKEAHA.120.033214. Access: abstract_metadata. Study: PMID34372670.

7. Khaw KT, Sharp SJ, Finikarides L et al. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ open. 2018. PMID 29511019. DOI: 10.1136/bmjopen-2017-020167. Access: abstract_metadata. Study: PMID29511019.

8. Laitinen TT, Nuotio J, Rovio SP et al. Dietary Fats and Atherosclerosis From Childhood to Adulthood. Pediatrics. 2020. PMID 32209700. DOI: 10.1542/peds.2019-2786. Access: abstract_metadata. Study: STRIP_NCT00223600.

9. Chisholm A, Mann J, Sutherland W et al. Dietary management of patients with familial hypercholesterolaemia treated with simvastatin. The Quarterly journal of medicine. 1992. PMID 1484945. DOI: not indexed in PubMed. Access: abstract_metadata. Study: PMID1484945.

10. Mensink RP, Zock PL, Katan MB et al. Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. Journal of lipid research. 1992. PMID 1431574. DOI: not indexed in PubMed. Access: abstract_metadata. Study: PMID1431574.

11. Dehghan M, Mente A, Zhang X et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet (London, England). 2017. PMID 28864332. DOI: 10.1016/S0140-6736(17)32252-3. Access: abstract_metadata. Study: PMID28864332.

12. Ho FK, Gray SR, Welsh P et al. Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants. BMJ (Clinical research ed.). 2020. PMID 32188587. DOI: 10.1136/bmj.m688. Access: abstract_metadata. Study: UK Biobank_dietary_analysis.

13. Li Y, Hruby A, Bernstein AM et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study. Journal of the American College of Cardiology. 2015. PMID 26429077. DOI: 10.1016/j.jacc.2015.07.055. Access: abstract_metadata. Study: PMID26429077.

14. Eichelmann F, Sellem L, Wittenbecher C et al. Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation. Circulation. 2022. PMID 35422138. DOI: 10.1161/CIRCULATIONAHA.121.056805. Access: abstract_metadata. Study: DIVAS_NCT01478958_EPIC Potsdam.

15. Zhang Y, Sun Y, Yu Q et al. Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank. eLife. 2024. PMID 38578269. DOI: 10.7554/eLife.90132. Access: abstract_metadata. Study: UK Biobank_PUFA_biomarkers.

16. Dearborn JL, Qiao Y, Guallar E et al. Polyunsaturated fats, carbohydrates and carotid disease: The Atherosclerosis Risk in Communities (ARIC) Carotid MRI study. Atherosclerosis. 2016. PMID 27234460. DOI: 10.1016/j.atherosclerosis.2016.05.024. Access: abstract_metadata. Study: PMID27234460.

17. Lehtovirta M, Pahkala K, Niinikoski H et al. Effect of Dietary Counseling on a Comprehensive Metabolic Profile from Childhood to Adulthood. The Journal of pediatrics. 2018. PMID 29397160. DOI: 10.1016/j.jpeds.2017.11.057. Access: abstract_metadata. Study: STRIP_NCT00223600.

18. Frantz ID, Dawson EA, Ashman PL et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis (Dallas, Tex.). 1989. PMID 2643423. DOI: 10.1161/01.atv.9.1.129. Access: abstract_metadata. Study: Minnesota_Coronary_Experiment.

19. Denke MA, Frantz ID. Response to a cholesterol-lowering diet: efficacy is greater in hypercholesterolemic subjects even after adjustment for regression to the mean. The American journal of medicine. 1993. PMID 8506889. DOI: 10.1016/0002-9343(93)90215-b. Access: abstract_metadata. Study: Minnesota_Coronary_Experiment.

20. Turpeinen O. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. Circulation. 1979. PMID 758101. DOI: 10.1161/01.cir.59.1.1. Access: abstract_metadata. Study: Finnish_Mental_Hospital_periods.

21. Turpeinen O, Karvonen MJ, Pekkarinen M et al. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. International journal of epidemiology. 1979. PMID 393644. DOI: 10.1093/ije/8.2.99. Access: abstract_metadata. Study: Finnish_Mental_Hospital_periods.

22. Miettinen M, Turpeinen O, Karvonen MJ et al. Dietary prevention of coronary heart disease in women: the Finnish mental hospital study. International journal of epidemiology. 1983. PMID 6840954. DOI: 10.1093/ije/12.1.17. Access: abstract_metadata. Study: Finnish_Mental_Hospital_periods.

23. Nuotio P, Lankinen MA, Meuronen T et al. Dietary n-3 alpha-linolenic and n-6 linoleic acids modestly lower serum lipoprotein(a) concentration but differentially influence other atherogenic lipoprotein traits: A randomized trial. Atherosclerosis. 2024. PMID 38714425. DOI: 10.1016/j.atherosclerosis.2024.117562. Access: abstract_metadata. Study: PMID38714425.

24. Rosqvist F, Iggman D, Kullberg J et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. Diabetes. 2014. PMID 24550191. DOI: 10.2337/db13-1622. Access: abstract_metadata. Study: LIPOGAIN_NCT01427140.

25. Rathnayake KM, Weech M, Lovegrove JA et al. Glu298Asp (rs1799983) Polymorphism Influences Postprandial Vascular Reactivity and the Insulin Response to Meals of Varying Fat Composition in Postmenopausal Women: Findings from the Randomized, Controlled Dietary Intervention and VAScular function (DIVAS)-2 Study. The Journal of nutrition. 2021. PMID 33693945. DOI: 10.1093/jn/nxaa394. Access: abstract_metadata. Study: DIVAS2_NCT02144454.

26. Perfilyev A, Dahlman I, Gillberg L et al. Impact of polyunsaturated and saturated fat overfeeding on the DNA-methylation pattern in human adipose tissue: a randomized controlled trial. The American journal of clinical nutrition. 2017. PMID 28275132. DOI: 10.3945/ajcn.116.143164. Access: abstract_metadata. Study: LIPOGAIN_NCT01427140.

27. Weech M, Altowaijri H, Mayneris-Perxachs J et al. Replacement of dietary saturated fat with unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases numbers of microparticles: findings from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. The American journal of clinical nutrition. 2018. PMID 29741564. DOI: 10.1093/ajcn/nqy018. Access: abstract_metadata. Study: DIVAS_NCT01478958.

28. Rosqvist F, Orho-Melander M, Kullberg J et al. Abdominal Fat and Metabolic Health Markers but Not PNPLA3 Genotype Predicts Liver Fat Accumulation in Response to Excess Intake of Energy and Saturated Fat in Healthy Individuals. Frontiers in nutrition. 2020. PMID 33344496. DOI: 10.3389/fnut.2020.606004. Access: abstract_metadata. Study: LIPOGAIN1_and2_pooled_SFA_arms.

29. Rosqvist F, Kullberg J, Ståhlman M et al. Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial. The Journal of clinical endocrinology and metabolism. 2019. PMID 31369090. DOI: 10.1210/jc.2019-00160. Access: abstract_metadata. Study: LIPOGAIN2_NCT02211612.

30. Rathnayake KM, Weech M, Jackson KG et al. Meal Fatty Acids Have Differential Effects on Postprandial Blood Pressure and Biomarkers of Endothelial Function but Not Vascular Reactivity in Postmenopausal Women in the Randomized Controlled Dietary Intervention and VAScular function (DIVAS)-2 Study. The Journal of nutrition. 2018. PMID 29546297. DOI: 10.1093/jn/nxx042. Access: abstract_metadata. Study: DIVAS2_NCT02144454.

31. Vafeiadou K, Weech M, Altowaijri H et al. Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. The American journal of clinical nutrition. 2015. PMID 26016869. DOI: 10.3945/ajcn.114.097089. Access: abstract_metadata. Study: DIVAS_NCT01478958.

32. Shatwan IM, Weech M, Jackson KG et al. Apolipoprotein E gene polymorphism modifies fasting total cholesterol concentrations in response to replacement of dietary saturated with monounsaturated fatty acids in adults at moderate cardiovascular disease risk. Lipids in health and disease. 2017. PMID 29169396. DOI: 10.1186/s12944-017-0606-3. Access: abstract_metadata. Study: DIVAS_NCT01478958.

33. Elmsjö A, Rosqvist F, Engskog MK et al. NMR-based metabolic profiling in healthy individuals overfed different types of fat: links to changes in liver fat accumulation and lean tissue mass. Nutrition & diabetes. 2015. PMID 26479316. DOI: 10.1038/nutd.2015.31. Access: abstract_metadata. Study: LIPOGAIN_NCT01427140.

34. Iggman D, Rosqvist F, Larsson A et al. Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). Journal of the American Heart Association. 2014. PMID 25319187. DOI: 10.1161/JAHA.114.001095. Access: abstract_metadata. Study: LIPOGAIN_NCT01427140.

35. Sellem L, Eichelmann F, Jackson KG et al. Replacement of dietary saturated with unsaturated fatty acids is associated with beneficial effects on lipidome metabolites: a secondary analysis of a randomized trial. The American journal of clinical nutrition. 2023. PMID 37062359. DOI: 10.1016/j.ajcnut.2023.03.024. Access: abstract_metadata. Study: DIVAS_NCT01478958_EPIC Potsdam.

36. Rathnayake KM, Weech M, Jackson KG et al. Impact of the Apolipoprotein E (epsilon) Genotype on Cardiometabolic Risk Markers and Responsiveness to Acute and Chronic Dietary Fat Manipulation. Nutrients. 2019. PMID 31480637. DOI: 10.3390/nu11092044. Access: abstract_metadata. Study: DIVAS_and_DIVAS2_genotype_reanalysis.

37. Rosqvist F, Bjermo H, Kullberg J et al. Fatty acid composition in serum cholesterol esters and phospholipids is linked to visceral and subcutaneous adipose tissue content in elderly individuals: a cross-sectional study. Lipids in health and disease. 2017. PMID 28372558. DOI: 10.1186/s12944-017-0445-2. Access: abstract_metadata. Study: PMID28372558.

38. Weech M, Vafeiadou K, Hasaj M et al. Development of a food-exchange model to replace saturated fat with MUFAs and n-6 PUFAs in adults at moderate cardiovascular risk. The Journal of nutrition. 2014. PMID 24717370. DOI: 10.3945/jn.114.190645. Access: abstract_metadata. Study: DIVAS_NCT01478958.

39. Bjermo H, Iggman D, Kullberg J et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. The American journal of clinical nutrition. 2012. PMID 22492369. DOI: 10.3945/ajcn.111.030114. Access: abstract_metadata. Study: PMID22492369.

40. Lennerz BS, Mey JT, Henn OH et al. Behavioral Characteristics and Self-Reported Health Status among 2029 Adults Consuming a "Carnivore Diet". Current developments in nutrition. 2021. PMID 34934897. DOI: 10.1093/cdn/nzab133. Access: full_text_partial. Study: PMID34934897.

41. Klement RJ, Matzat JS. Subjective Experiences and Blood Parameter Changes in Individuals From Germany Following a Self-Conceived "Carnivore Diet": An Explorative Study. Cureus. 2025. PMID 40385902. DOI: 10.7759/cureus.82521. Access: abstract_metadata. Study: PMID40385902.

42. Ramsden CE, Zamora D, Majchrzak-Hong S et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ (Clinical research ed.). 2016. PMID 27071971. DOI: 10.1136/bmj.i1246. Access: full_text_partial. Study: Minnesota_Coronary_Experiment.

43. Ramsden CE, Zamora D, Leelarthaepin B et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ (Clinical research ed.). 2013. PMID 23386268. DOI: 10.1136/bmj.e8707. Access: full_text_partial. Study: PMID23386268.

44. Hodgson JM, Wahlqvist ML, Boxall JA et al. Can linoleic acid contribute to coronary artery disease? The American journal of clinical nutrition. 1993. PMID 8192728. DOI: 10.1093/ajcn/58.2.228. Access: abstract_metadata. Study: PMID8192728.

45. Kuriyan R, Gopinath N, Vaz M et al. Use of rice bran oil in patients with hyperlipidaemia. The National medical journal of India. 2005. PMID 16483027. DOI: not indexed in PubMed. Access: abstract_metadata. Study: PMID16483027.

46. de Goede J, Geleijnse JM, Boer JM et al. Linoleic acid intake, plasma cholesterol and 10-year incidence of CHD in 20,000 middle-aged men and women in the Netherlands. The British journal of nutrition. 2012. PMID 21816117. DOI: 10.1017/S0007114511003837. Access: abstract_metadata. Study: PMID21816117.

47. Khaw KT, Friesen MD, Riboli E et al. Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study. PLoS medicine. 2012. PMID 22802735. DOI: 10.1371/journal.pmed.1001255. Access: abstract_metadata. Study: PMID22802735.

48. Dayton S, Hashimoto S, Dixon W et al. Composition of lipids in human serum and adipose tissue during prolonged feeding of a diet high in unsaturated fat. Journal of lipid research. 1966. PMID 5900208. DOI: not indexed in PubMed. Access: abstract_metadata. Study: LA_Veterans_unsaturated_diet.

49. Hjermann I, Velve Byre K, Holme I et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet (London, England). 1981. PMID 6118715. DOI: 10.1016/s0140-6736(81)91338-6. Access: abstract_metadata. Study: Oslo_primary_prevention_diet_antismoking_1232.

50. Holme I, Retterstøl K, Norum KR et al. Lifelong benefits on myocardial infarction mortality: 40-year follow-up of the randomized Oslo diet and antismoking study. Journal of internal medicine. 2016. PMID 26924204. DOI: 10.1111/joim.12485. Access: abstract_metadata. Study: Oslo_primary_prevention_diet_antismoking_1232.

51. Nielsen MH, Frydenberg M, Bork CS et al. Linoleic acid in adipose tissue and the risk of myocardial infarction: a case-cohort study. European journal of nutrition. 2021. PMID 33687534. DOI: 10.1007/s00394-021-02526-y. Access: abstract_metadata. Study: PMID33687534.

52. Liu Q, Kong Y, Kang H et al. Circulating polyunsaturated fatty acids percentages and coronary artery disease incidence and mortality: Observational and Mendelian randomization analyses. Clinical nutrition (Edinburgh, Scotland). 2025. PMID 40199060. DOI: 10.1016/j.clnu.2025.03.020. Access: abstract_metadata. Study: UK Biobank_PUFA_observational_and_genetic.

53. Wu JH, Lemaitre RN, King IB et al. Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: the Cardiovascular Health Study. Circulation. 2014. PMID 25124495. DOI: 10.1161/CIRCULATIONAHA.114.011590. Access: abstract_metadata. Study: PMID25124495.

54. de Oliveira Otto MC, Wu JH, Baylin A et al. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis. Journal of the American Heart Association. 2013. PMID 24351702. DOI: 10.1161/JAHA.113.000506. Access: abstract_metadata. Study: PMID24351702.

55. Delgado GE, März W, Lorkowski S et al. Omega-6 fatty acids: Opposing associations with risk-The Ludwigshafen Risk and Cardiovascular Health Study. Journal of clinical lipidology. 2017. PMID 28647413. DOI: 10.1016/j.jacl.2017.05.003. Access: abstract_metadata. Study: PMID28647413.

56. Borges MC, Haycock PC, Zheng J et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. BMC medicine. 2022. PMID 35692035. DOI: 10.1186/s12916-022-02399-w. Access: abstract_metadata. Study: UK Biobank_PUFA_GWAS_instrument.

57. Zhuang P, Liu X, Li Y et al. Circulating fatty acids, genetic risk, and incident coronary artery disease: A prospective, longitudinal cohort study. Science advances. 2023. PMID 37738352. DOI: 10.1126/sciadv.adf9037. Access: abstract_metadata. Study: UK Biobank_PUFA_genetic_risk_cohort.

58. Park S, Lee S, Kim Y et al. Causal Effects of Serum Levels of n-3 or n-6 Polyunsaturated Fatty Acids on Coronary Artery Disease: Mendelian Randomization Study. Nutrients. 2021. PMID 33924952. DOI: 10.3390/nu13051490. Access: abstract_metadata. Study: UK Biobank_and_CARDIoGRAM_fatty_acid_instruments.

59. Harris WS, Tintle NL, Ramachandran VS. Erythrocyte n-6 Fatty Acids and Risk for Cardiovascular Outcomes and Total Mortality in the Framingham Heart Study. Nutrients. 2018. PMID 30572606. DOI: 10.3390/nu10122012. Access: abstract_metadata. Study: Framingham_Offspring_fatty_acids.

60. Lankinen MA, Fauland A, Shimizu BI et al. Inflammatory response to dietary linoleic acid depends on FADS1 genotype. The American journal of clinical nutrition. 2019. PMID 30624587. DOI: 10.1093/ajcn/nqy287. Access: abstract_metadata. Study: PMID30624587.

Source-specific evidence cards

[1] Cretan Mediterranean diet for prevention of coronary heart disease.

Shows: The Lyon secondary-prevention randomized dietary programme substantially reduced recurrent coronary events while lowering saturated fat and linoleic acid and increasing oleic and alpha-linolenic acids.

Does not show: This is a multicomponent Mediterranean dietary contrast, not isocaloric saturated-fat replacement by linoleic-rich oils; it overlaps the parent trial reported in PMID7911176.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[2] Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.

Shows: In 605 post-infarct patients, the randomized Mediterranean alpha-linolenic-rich diet reduced cardiac death or nonfatal infarction over about 27 months without a serum-lipid difference.

Does not show: Linoleic intake was lower, not higher, and many food and fatty-acid changes were bundled; the attached erratum's identifier and details were not supplied, and this is the same Lyon trial as PMID7754988.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC2.

[3] APOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and Mortality.

Shows: Prospective fatty-acid measurements in two older-adult cohorts associated higher linoleic acid with lower stroke and mortality among APOE epsilon4 carriers.

Does not show: The exploratory genotype subgroup and measured plasma exposure are not randomized isocaloric replacement; the reported linoleic benefits were stroke and mortality rather than isolated coronary events.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[4] Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial.

Shows: A 48-patient randomized comprehensive lifestyle programme showed coronary-angiographic regression after one year compared with usual care.

Does not show: Vegetarian diet, smoking cessation, exercise and stress management were bundled; angiographic lesions are not coronary events and no carnivore comparator or isolated linoleic replacement was tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[5] Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Shows: JELIS randomized 18645 Japanese hypercholesterolemic patients to EPA plus statin or statin alone and reduced the composite major-coronary endpoint over 4.6 years.

Does not show: This omega3 pharmacological adjunct is a composition-confounding comparator, not saturated-fat replacement by linoleic oils; coronary mortality did not differ, open-label treatment matters, and an attached unspecified erratum is flagged.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC2.

[6] Mediterranean Diet Reduces Atherosclerosis Progression in Coronary Heart Disease: An Analysis of the CORDIOPREV Randomized Controlled Trial.

Shows: CORDIOPREV secondary analysis associated Mediterranean allocation with improved carotid thickness and plaque measures versus low-fat allocation over five to seven years.

Does not show: Carotid morphology is a surrogate and extra-virgin olive oil is predominantly monounsaturated; this does not isolate linoleic replacement or establish carnivore superiority, and erratum PMID34694867 attaches to the parent report.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID34694867. Subclaims: SC2, SC4.

[7] Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women.

Shows: A 94-person randomized four-week butter, coconut or olive-oil study found higher LDL cholesterol with butter, while coconut and olive oils did not differ significantly.

Does not show: These oils were not linoleic-rich and consumption could supplement rather than replace food isocalorically; food-specific biomarker effects cannot substitute for coronary-event benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[8] Dietary Fats and Atherosclerosis From Childhood to Adulthood.

Shows: A secondary STRIP analysis linked achieving a childhood dietary-fat target with more favourable aortic thickness and distensibility through young adulthood.

Does not show: The analysed exposure was achieved diet rather than randomized allocation, with a surrogate endpoint and mostly pediatric horizon; it does not establish adult coronary-event causation or isolated linoleic replacement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[9] Dietary management of patients with familial hypercholesterolaemia treated with simvastatin.

Shows: A 19-person randomized crossover found lower LDL-related plasma cholesterol under a lower-fat diet despite concurrent simvastatin for familial hypercholesterolemia.

Does not show: The dietary contrast was not isolated isocaloric linoleic substitution; lipid lowering in a familial clinical population is not an observed coronary-event endpoint.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[10] Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans.

Shows: Three controlled feeding experiments compared saturated, cis-unsaturated and trans-unsaturated fat effects on lipoprotein[a], with markedly higher values under trans exposure.

Does not show: The abstract is publisher-truncated before the linoleic arm's full results; the exposure was short and a lipid marker, so results cannot demonstrate long-term coronary harm from usual linoleic oils.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[11] Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.

Shows: PURE associated higher carbohydrate intake with mortality while fat classes were not significantly associated with myocardial infarction or cardiovascular mortality across 18 countries.

Does not show: Diet was observational and nutritional adequacy, socioeconomic context and replacement foods differ; neither a null saturated-fat association nor lower all-cause mortality establishes carnivore superiority or a randomized linoleic substitution effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[12] Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants.

Shows: UK Biobank dietary analysis found nonlinear macronutrient-mortality associations, including different estimated risks at moderate versus high polyunsaturated-fat intakes.

Does not show: Diet questionnaires, selection and residual confounding prevent treating macronutrient curves as causal replacement-dose rules; erratum PMID32371385 attaches and coronary events differ from total mortality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID32371385. Subclaims: SC2, SC3.

[13] Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective Cohort Study.

Shows: NHS and HPFS prospective substitution models associated replacing 5% energy saturated fat with PUFA with 25% lower coronary risk; refined carbohydrate replacement was not beneficial.

Does not show: Modelled substitution is not assigned isocaloric replacement and PUFA composition and healthy-behaviour confounding remain; these repeated cohorts are not independent randomized fatty-acid lines.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[14] Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.

Shows: EPIC Potsdam lipidomics associated selected lipids with incident disease, and the 16-week DIVAS randomized dietary-fat modification changed several risk-associated lipid species favourably.

Does not show: The diet contained mixed monounsaturated and omega6 fats; connecting biomarker changes to a separate cohort's events does not demonstrate coronary-event prevention or mediator necessity.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[15] Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank.

Shows: UK Biobank associated a higher plasma omega6-to-omega3 ratio with mortality, while each fatty-acid class individually associated inversely with mortality and omega3 had the stronger association.

Does not show: A ratio can rise through reduced omega3 and does not identify omega6 toxicity; circulating proportions and mortality are not randomized usual-exposure inflammatory harm, and UpdateOf PMID36711941 is attached without an extra primary row.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. UpdateOf: PMID36711941. Subclaims: SC2, SC3.

[16] Polyunsaturated fats, carbohydrates and carotid disease: The Atherosclerosis Risk in Communities (ARIC) Carotid MRI study.

Shows: The ARIC carotid MRI study found no independent association of PUFA intake or glycemic index with high-risk plaque features after vascular-risk adjustment.

Does not show: Questionnaire exposure, selected attendees and surrogate plaques do not test randomized coronary events; a surrogate null does not refute every dietary replacement effect.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[17] Effect of Dietary Counseling on a Comprehensive Metabolic Profile from Childhood to Adulthood.

Shows: Repeated randomized STRIP counselling lowered saturated intake and LDL-related lipid measures while increasing circulating omega3 and omega6 proportions from childhood through young adulthood.

Does not show: Multiple dietary changes and a pediatric horizon limit isolated adult linoleic-oil inference; the shared STRIP cohort and biomarkers are not a separate coronary-event trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[18] Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey.

Shows: The original Minnesota randomized institutional trial lowered serum cholesterol but found no overall cardiovascular-event, cardiovascular-death or total-mortality difference.

Does not show: Mean dietary exposure was 384 days despite a 4.5-year trial and many short stays; intervention changed dietary cholesterol and historical fat sources, and later recovered reports share this trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[19] Response to a cholesterol-lowering diet: efficacy is greater in hypercholesterolemic subjects even after adjustment for regression to the mean.

Shows: A Minnesota subgroup analysis using repeated measurements found greater cholesterol reduction with higher baseline cholesterol after adjusting for regression to the mean.

Does not show: This same-trial lipid response does not demonstrate coronary benefit or identify outcome-defined responders; single baseline measurements can exaggerate apparent subgroup response.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[20] Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes.

Shows: The Finnish two-hospital dietary intervention associated replacement of dairy fats with vegetable oils with lower male coronary mortality over its 12-year crossover.

Does not show: Hospital-period allocation, institutional medication and population changes can confound the result; this is a report from the same Finnish study as PMID393644 and 6840954 rather than individual randomization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[21] Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study.

Shows: The Finnish two-hospital crossover found about half the male electrocardiographic-coronary or coronary-death incidence during lower-saturated higher-polyunsaturated dietary periods.

Does not show: Although metadata labels randomized trial, the described allocation is hospital-period diet reversal and should not be treated as patient randomization; mixed dietary changes and historical context restrict isolated linoleic inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[22] Dietary prevention of coronary heart disease in women: the Finnish mental hospital study.

Shows: The Finnish women's hospital-period intervention lowered cholesterol and coronary incidence estimates, but the coronary difference was not statistically significant.

Does not show: Shared hospital-period design and possible medication or population changes limit inference; nonsignificance is not proof of equivalence, and male/female reports are grouped under one parent study.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[23] Dietary n-3 alpha-linolenic and n-6 linoleic acids modestly lower serum lipoprotein(a) concentration but differentially influence other atherogenic lipoprotein traits: A randomized trial.

Shows: An 118-man randomized oil comparison lowered lipoprotein[a] under both linoleic-rich sunflower and alpha-linolenic-rich Camelina diets, with larger LDL-related reductions under the latter.

Does not show: There was no retained saturated-fat comparator and no coronary outcomes; FADS genotype did not modify the lipid response, so metabolic genotype assumptions cannot be treated as established mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[24] Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans.

Shows: The 39-person LIPOGAIN randomized overfeeding trial found greater liver and visceral-fat accumulation with palm-oil muffins than sunflower-oil muffins despite similar weight gain.

Does not show: This is an excess-energy context and ectopic-fat or body-composition outcomes, not usual-intake inflammatory coronary harm or an isocaloric clinical-event trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[25] Glu298Asp (rs1799983) Polymorphism Influences Postprandial Vascular Reactivity and the Insulin Response to Meals of Varying Fat Composition in Postmenopausal Women: Findings from the Randomized, Controlled Dietary Intervention and VAScular function (DIVAS)-2 Study.

Shows: A 32-woman DIVAS2 postprandial crossover found selected genotype-dependent vascular and insulin responses to saturated, monounsaturated and omega6 meals.

Does not show: Genotyping was retrospective, the interaction was not consistent across absolute and incremental vascular measures, and acute biomarkers do not establish clinically important inflammatory cardiovascular harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[26] Impact of polyunsaturated and saturated fat overfeeding on the DNA-methylation pattern in human adipose tissue: a randomized controlled trial.

Shows: A LIPOGAIN secondary randomized-overfeeding analysis found distinct adipose methylation changes after saturated and omega6 fat excess, including shared overfeeding effects.

Does not show: Gene methylation is not evidence of clinical inflammation or coronary injury; the same parent trial is grouped and erratum PMID28673906 attaches without another primary row.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID28673906. Subclaims: SC3.

[27] Replacement of dietary saturated fat with unsaturated fats increases numbers of circulating endothelial progenitor cells and decreases numbers of microparticles: findings from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study.

Shows: Sixteen-week isoenergetic DIVAS replacement with omega6 or monounsaturated fats lowered selected circulating endothelial and platelet microparticles compared with saturated fat.

Does not show: Novel vascular markers are not clinical events and endothelial-progenitor increases were confined to the monounsaturated arm; this is the same DIVAS parent as its lipid and vascular reports.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[28] Abdominal Fat and Metabolic Health Markers but Not PNPLA3 Genotype Predicts Liver Fat Accumulation in Response to Excess Intake of Energy and Saturated Fat in Healthy Individuals.

Shows: A pooled LIPOGAIN1 and 2 secondary analysis associated baseline metabolic characteristics with liver-fat response to saturated-fat overfeeding.

Does not show: Only the saturated-fat arms were pooled and predictors were observational; overlapping parent trials and hypercaloric exposure do not demonstrate usual linoleic-oil inflammation or harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[29] Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial.

Shows: LIPOGAIN2 randomized 61 adults to excess-energy palm or sunflower muffins and found higher liver fat, ceramides and atherogenic lipids with saturated fat despite similar weight gain.

Does not show: The report centres on secondary or exploratory outcomes and excess calories; biomarker and liver-fat differences do not establish coronary-event reduction or universally harmless linoleic oils.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[30] Meal Fatty Acids Have Differential Effects on Postprandial Blood Pressure and Biomarkers of Endothelial Function but Not Vascular Reactivity in Postmenopausal Women in the Randomized Controlled Dietary Intervention and VAScular function (DIVAS)-2 Study.

Shows: DIVAS2 randomized meal fat composition produced lower soluble ICAM1 after omega6 meals but no primary flow-mediated-dilatation difference.

Does not show: An acute endothelial activation marker does not establish long-term clinical inflammation or safety; the primary vascular null and same-trial genotype reanalysis are retained.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[31] Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study.

Shows: The 195-person 16-week isoenergetic DIVAS trial lowered LDL cholesterol with saturated-fat replacement by omega6 PUFA, but its primary flow-mediated-dilatation endpoint was null.

Does not show: Its estimated 17-20% mortality reduction was extrapolated from lipid change and was not an observed mortality or coronary-event result; mixed monounsaturated replacement and short follow-up retain scope.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[32] Apolipoprotein E gene polymorphism modifies fasting total cholesterol concentrations in response to replacement of dietary saturated with monounsaturated fatty acids in adults at moderate cardiovascular disease risk.

Shows: A retrospective DIVAS genotype analysis found one APOE interaction with cholesterol response under monounsaturated replacement, with other variants null.

Does not show: Small genotype subgroups and retrospective interactions do not define baseline-validated linoleic responders or add an independent causal line to the shared trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[33] NMR-based metabolic profiling in healthy individuals overfed different types of fat: links to changes in liver fat accumulation and lean tissue mass.

Shows: LIPOGAIN metabolomic reanalysis found a few differential plasma metabolites under saturated versus omega6 overfeeding and correlations with fat compartments.

Does not show: These are candidate metabolic markers, not proven mediators or coronary outcomes; the 39 participants overlap the original overfeeding report.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[34] Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study).

Shows: LIPOGAIN sunflower versus palm overfeeding improved selected atherogenic lipid ratios, while endothelial activation markers increased with weight gain across both fat arms.

Does not show: The common excess-energy response cannot be attributed specifically to linoleic acid; shared-trial lipid ratios and acute-risk biomarkers do not establish long-term coronary harm or benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[35] Replacement of dietary saturated with unsaturated fatty acids is associated with beneficial effects on lipidome metabolites: a secondary analysis of a randomized trial.

Shows: A DIVAS secondary lipidomic analysis linked dietary-fat-responsive plasma species to incident disease associations in EPIC Potsdam.

Does not show: Different trial and cohort populations and multiple fat changes prevent an identified mediator claim; the same 113 DIVAS subset and EPIC Potsdam case-cohorts overlap PMID35422138.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[36] Impact of the Apolipoprotein E (epsilon) Genotype on Cardiometabolic Risk Markers and Responsiveness to Acute and Chronic Dietary Fat Manipulation.

Shows: Retrospective DIVAS and DIVAS2 genotyping associated APOE with selected baseline markers and exploratory responses, especially under monounsaturated exposure.

Does not show: Genetic stratification of a shared trial is not Mendelian randomization and requires prospective replication; genotype-marker correlations do not establish linoleic inflammatory harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[37] Fatty acid composition in serum cholesterol esters and phospholipids is linked to visceral and subcutaneous adipose tissue content in elderly individuals: a cross-sectional study.

Shows: In 287 PIVUS older adults, serum linoleic proportions associated inversely with visceral and other fat depots after covariate adjustment.

Does not show: Cross-sectional fatty-acid proportions and body-fat surrogates can reflect metabolism and diet, not causal replacement or clinical inflammatory cardiovascular effects.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[38] Development of a food-exchange model to replace saturated fat with MUFAs and n-6 PUFAs in adults at moderate cardiovascular risk.

Shows: The 195-person DIVAS food-exchange report verified broadly achieved isoenergetic fat-composition targets with little change in other macronutrients or anthropometrics.

Does not show: This is original adherence and exposure data from the same randomized parent, not a separate coronary-event trial or proof that every individual met the prescription.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[39] Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial.

Shows: A 67-person 10-week isocaloric randomized vegetable omega6 versus butter trial found lower liver fat and selected inflammatory signalling markers with PUFA, without a proinflammatory or oxidative-stress signal.

Does not show: Some favourable lipid estimates were restricted to postrandomization compliant participants and cannot define clinical beneficiaries; markers and liver fat are not coronary outcomes or universal safety proof.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[40] Behavioral Characteristics and Self-Reported Health Status among 2029 Adults Consuming a "Carnivore Diet".

Shows: A 2029-person social-media carnivore survey reported perceived symptom and weight improvements alongside high satisfaction and high LDL cholesterol in a laboratory-reporting subset.

Does not show: Maintainer recruitment, self-report, missing measurements and no concurrent comparison prevent long-term cardiovascular superiority or clinical event safety conclusions.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph 0, 1:Methods:paragraph 1, 1:Methods:paragraph 2, 1:Methods:paragraph 3, 1:Methods:paragraph 5, 2:Results:paragraph 7, 2:Results:paragraph 12, 2:Results:paragraph 18. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[41] Subjective Experiences and Blood Parameter Changes in Individuals From Germany Following a Self-Conceived "Carnivore Diet": An Explorative Study.

Shows: A 24-person exploratory German carnivore study collected before-and-after laboratory reports and perceived benefits, with significantly higher total and LDL cholesterol after adoption.

Does not show: Self-selected participants, varied diet definitions, short eligibility and uncontrolled cointerventions cannot establish long-term event superiority; favourable triglycerides or HbA1c do not cancel LDL-related uncertainty.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[42] Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73).

Shows: Original recovered Minnesota trial analyses confirmed cholesterol lowering without a reported mortality benefit; selected autopsy files and longitudinal cholesterol-mortality associations challenged a simple marker-to-benefit prediction.

Does not show: Only the original recovered-data component earns primary credit: full randomized raw data were unavailable and autopsies partly recovered; cholesterol-death association in both arms is not randomized mediator harm, and the examined 2024 erratum PMID38942429 updates a thesis link rather than study numbers.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph 0, 1:Methods:paragraph 6, 1:Methods:paragraph 9, 1:Methods:paragraph 12, 1:Methods:paragraph 18, 1:Methods:paragraph 19, 1:Methods:paragraph 20, 1:Methods:paragraph 30, 1:Methods:paragraph 32, 1:Methods:paragraph 35, 2:Results:paragraph 5, 2:Results:paragraph 8, 2:Results:paragraph 17, 2:Results:paragraph 18, 2:Results:paragraph 19, 2:Results:paragraph 22. No complete-paper or supplement audit claimed. ErratumIn: PMID38942429. Subclaims: SC1, SC2, SC3.

[43] Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis.

Shows: Original recovered Sydney data from 458 post-coronary-event men showed lower cholesterol but higher coronary and cardiovascular mortality under safflower-oil and margarine substitution over median 39 months.

Does not show: Only recovered original trial data earns credit, not its meta-analysis; actual all-cause P=.051 was borderline, historical margarine and high LA exposure constrain usual-modern-oil inference, and an unspecified erratum attaches.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph 1, 1:Methods:paragraph 2, 1:Methods:paragraph 4, 1:Methods:paragraph 5, 1:Methods:paragraph 7, 2:Results:paragraph 0, 2:Results:paragraph 12, 2:Results:paragraph 13, 2:Results:paragraph 17, 2:Results:paragraph 19. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC1, SC2, SC3.

[44] Can linoleic acid contribute to coronary artery disease?

Shows: A 226-patient coronary-angiography series associated higher adipose and platelet linoleic proportions with more extensive coronary disease.

Does not show: Cross-sectional referred-patient selection, residual confounding and reverse causation prevent treating this adverse association as randomized oil harm or an identified inflammatory mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[45] Use of rice bran oil in patients with hyperlipidaemia.

Shows: A 14-person randomized home-use crossover found lower total cholesterol and triglycerides with rice-bran than sunflower oil, while the LDL difference was nonsignificant.

Does not show: An oil-versus-oil food-matrix comparison has no saturated-fat arm or coronary endpoint; small unblinded home-use periods cannot attribute differences solely to linoleic content or establish risk reduction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[46] Linoleic acid intake, plasma cholesterol and 10-year incidence of CHD in 20,000 middle-aged men and women in the Netherlands.

Shows: A 20069-person Dutch prospective cohort found no linoleic-intake association with coronary incidence over ten years despite a4-5% energy LA-versus-carbohydrate difference.

Does not show: The replacement comparator was largely carbohydrate rather than saturated fat, and questionnaire exposure and 280 events limit precision; the null does not establish clinical equivalence of oil replacement.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[47] Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study.

Shows: EPIC Norfolk baseline plasma phospholipid measurements associated higher omega6 fatty-acid concentrations with lower subsequent coronary risk after adjustment.

Does not show: Measured circulating fats reflect metabolism as well as intake, and heterogeneous individual fatty-acid associations prevent equating total omega6 with a randomized linoleic-rich oil substitution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[48] Composition of lipids in human serum and adipose tissue during prolonged feeding of a diet high in unsaturated fat.

Shows: The randomized Veterans prolonged-feeding cohort showed lower serum cholesterol and substantial sustained tissue-linoleic enrichment under unsaturated-fat replacement over up to five years.

Does not show: This original exposure and lipid report does not itself give coronary-event counts; it belongs to the same Veterans parent as its clinical reports and cannot verify a clinical crossing from markers alone.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[49] Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men.

Shows: The 1232-man randomized Oslo primary-prevention programme reduced first infarction or sudden-death incidence by 47% over five years with diet and antismoking advice.

Does not show: Diet composition, fish, weight control and smoking changes were bundled, so this positive cannot identify the effect of isolated linoleic-rich oil replacement; later follow-up is the same study.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[50] Lifelong benefits on myocardial infarction mortality: 40-year follow-up of the randomized Oslo diet and antismoking study.

Shows: Forty-year follow-up of the randomized Oslo diet-and-antismoking programme found a borderline reduction in first-infarction mortality, with all-cause benefit limited to earlier follow-up.

Does not show: Long-term events reflect the same bundled intervention and subsequent exposures; it is not an independent oil trial or evidence of lifelong universal mortality benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[51] Linoleic acid in adipose tissue and the risk of myocardial infarction: a case-cohort study.

Shows: A Danish case-cohort study with 2819 incident infarctions found no association between baseline adipose linoleic acid and infarction risk over 16 years, including shorter-horizon analyses.

Does not show: A tissue biomarker reflects long-term exposure and metabolism rather than randomized replacement; null associations do not prove equivalence or inflammatory harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[52] Circulating polyunsaturated fatty acids percentages and coronary artery disease incidence and mortality: Observational and Mendelian randomization analyses.

Shows: A 203373-person UK Biobank study found inverse observational PUFA-percentage associations with coronary outcomes and genetically proxied omega6 support for lower coronary incidence, with sex differences.

Does not show: The abstract's causal positive is total omega6 percentage rather than isolated LA-rich oil intake or isocaloric replacement; composition scaling, pleiotropy and subgroup precision remain relevant.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[53] Circulating omega-6 polyunsaturated fatty acids and total and cause-specific mortality: the Cardiovascular Health Study.

Shows: The Cardiovascular Health Study associated higher circulating linoleic acid with lower total and especially nonarrhythmic coronary mortality in older adults.

Does not show: Prospective biomarker associations challenge a blanket harm narrative but retain residual confounding and metabolic-exposure ambiguity; they are not assigned saturated-fat substitution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[54] Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis.

Shows: MESA found no significant association of dietary or circulating linoleic acid with incident composite cardiovascular disease, whereas marine omega3 associations were inverse.

Does not show: Only 189 composite events limit precision, and exposure biomarkers and dietary estimates do not implement isocaloric replacement; a class-level PUFA benefit cannot be assigned automatically to every species.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[55] Omega-6 fatty acids: Opposing associations with risk-The Ludwigshafen Risk and Cardiovascular Health Study.

Shows: The Ludwigshafen angiography cohort reported opposing mortality associations across individual omega6 species, with linoleic acid and gamma-linolenic acid described as favourable.

Does not show: Referral selection, baseline disease and circulating metabolism confound interpretation; the abstract contains an internally inconsistent interval for one non-LA result, which is not used numerically here.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[56] Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants.

Shows: A large fatty-acid GWAS and MR analysis found inconsistent linoleic estimates across cardiovascular endpoints and methods, with lipoprotein and FADS locus sensitivity.

Does not show: Genetically proxied circulating concentration is not dietary isocaloric replacement; horizontal pleiotropy and shared lipid pathways restrict interpretation rather than proving either clinical benefit or inflammatory harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[57] Circulating fatty acids, genetic risk, and incident coronary artery disease: A prospective, longitudinal cohort study.

Shows: A UK Biobank cohort associated higher circulating linoleic acid with increased coronary risk within a high-genetic-risk subgroup, while other PUFA associations differed.

Does not show: A baseline genetic stratum is measurable before outcomes but an observational subgroup result does not establish a causal LA-risk interaction or justify universal toxicity; circulating composition and residual confounding remain.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[58] Causal Effects of Serum Levels of n-3 or n-6 Polyunsaturated Fatty Acids on Coronary Artery Disease: Mendelian Randomization Study.

Shows: Allele-score and summary-level MR supported lower coronary risk with genetically predicted linoleic acid, while other fatty acids showed different directions.

Does not show: Instruments perturb endogenous metabolism rather than assigned dietary replacement, may affect multiple lipids and share cohorts or loci with other MR papers; this is genuine causal-inference support with scope and validity limits.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[59] Erythrocyte n-6 Fatty Acids and Risk for Cardiovascular Outcomes and Total Mortality in the Framingham Heart Study.

Shows: Framingham offspring erythrocyte omega6 measurements showed little independent association with cardiovascular outcomes or mortality after marine omega3 adjustment.

Does not show: The same cohort contributes to other fatty-acid analyses, and biomarker covariance and limited event counts prevent interpreting the null as equivalence or oil-swap causation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[60] Inflammatory response to dietary linoleic acid depends on FADS1 genotype.

Shows: FADSDIET exposed 62 genotype-selected healthy men to a four-week linoleic-enriched diet and found differing CRP and fatty-acid responses by FADS1 genotype.

Does not show: Both genotype groups received enrichment without a randomized saturated-fat comparator, and short marker changes or correlations do not demonstrate clinically important inflammatory coronary harm at usual intake.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• reader-summary.json
• research-timeline.json
• saturated-fat-linoleic-coronary.review.md
• saturated-fat-linoleic-coronary.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 60 · load-bearing claims: 65 · verified: 65 · unverified: 0 · contradicted: 0 · schema 5.3